Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Suven Life Sciences Gains 5%; BSE HEALTHCARE Index Up 0.9%
Mon, 22 Jul 15:37

Suven Life Sciences Gains 5%; BSE HEALTHCARE Index Up 0.9%Image source: DNY59/www.istockphoto.com

Suven Life Sciences share price has zoomed 5% and is presently trading at Rs 132.0.

Meanwhile, the BSE HEALTHCARE index is at 38,507.2 (up 0.9%).

Among the top gainers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (up 3.8%) and SUVEN PHARMACEUTICALS (up 3.7%).

Jubilant Pharmova (down 3.6%) and ASTRAZENECA PHARMA (down 1.7%) are among the top losers today.

Over the last one year, Suven Life Sciences has moved up from Rs 63.2 to Rs 132.0, registering a gain of Rs 68.7 (up 108.7%).

On the other hand, the BSE HEALTHCARE index has moved up from 26,342.4 to 38,507.2, registering a gain of 46.2% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 97.2%), Lupin (up 92.8%) and Cadila Healthcare (up 92.4%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,506.6 (down 0.1%).

The top losers among the BSE Sensex today are Reliance Ind. (down 3.4%) and Kotak Bank (down 3.3%). The most traded stocks in the BSE Sensex are Tata Steel and HDFC Bank.

In the meantime, NSE Nifty is at 24,515.9 (down 0.1%). Wipro and Reliance Ind. are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 66,795.1 to 80,506.6, registering a gain of 13,711.5 points (up 20.5%).

Suven Life Sciences Financial Update...

Suven Life Sciences net profit grew 4.0% YoY to Rs -265 million for the quarter ended March 2024, compared to a loss of Rs 276 million a year ago. Net sales declined 8.7% to Rs 24 million during the period as against Rs 26 million in January-March 2023.

For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.

The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -27.4.


Equitymaster requests your view! Post a comment on "Suven Life Sciences Gains 5%; BSE HEALTHCARE Index Up 0.9%". Click here!